ESR1 and breast carcinoma: Thus, inhibiting WEE1 may overcome resistance to standard therapy in ER + breast cancer (Fallah et al., 2021), and it holds significant implications for Rb-deficient, ER + resistant breast cancer cells (Kumarasamy et al., 2022).